关于动研所举行学术报告的通知

为了营造学术氛围，拓展学术领域，增长学术知识，动研所邀请奥地利维也纳医科大学教授Richard Moriggl到我所进行学术交流。

具体安排通知如下：

报告题目：The JAK-STAT Core Cancer Pathway: Modeling and Targeting Concepts

报告人： Richard Moriggl

报告时间： 2月24日 星期五 10:00

报告地点：动研所-第一会议室

报告人介绍：

Richard Moriggl, now a professor at Medical University of Vienna, University of Veterinary Medicine in Vienna, Institute of Ludwig Edward Boltzmann Cancer. Dr. Moriggl studied biotechnology in Germany and did PhD in 1997, working on cytokine signaling with Prof. Groner, Friedrich Miescher Institute, Basel, Switzerland and Institute of Experimental Cancer Research, Freiburg, Germany. After a postdoctoral fellowship at St. Jude Children’s Research Hospital in Memphis, USA, in biochemistry, immunology and JAK-STAT signaling with Prof. Ihle. After 2000, he moved to the group of Prof. Beug, at Institute of Molecular Pathology, Vienna, engaged in the hematopoiesis and hematopoietic cancer development. Richard Moriggl was appointed professor at Ludwig Boltzmann Institute for Cancer Research (LBI-CR) since 2005, and served as professor for two medical research performing universities (University of Veterinary Medicine, Vienna, Austria; Medical University Vienna, Vienna, Austria) in 2014. Richard Moriggl described how oligomeric STAT5 transcription factors drive hematopoietic cancers, where recently a new metabolic O-GlcNAc sensor on STAT5 was discovered which essential for cytokine-driven transformation. Moreover, he made contributions to the essential interaction of the hepatic glucocorticoid receptor (GR) and STAT5 for body growth, sexual differentiation and metabolism. The group of RM mainly studies hematopoietic cancer, melanoma, sarcoma, colon and liver cancer development or metabolic consequences, using as model system transgenic mice and comparative pathology studies with patient samples. The main focus is work on the JAK-STAT core cancer pathway either by loss or gain of function approach. RM served as author in >125 peer reviewed publications. The team of RM performs basic and translational cancer research with a main focus on the generation and utilization of gene targeted mouse models, the exploration of new therapies and comparative pathology. The lecture will focus on unpublished transgenic STAT5 mouse models, insights into posttranslational modifications of STAT5A and STAT5B guiding oligomerization and gene transcription with graded pYSTAT5A or pYSTAT5B activity and consequences of chromatin landscaping. We work on mechanistic insights into gene regulation for neoplastic lymphocytes or myeloid cell types either alone or in combination with cytokine or aberrant driver kinase context. The lecture will provide insights into blocking too much pYSTAT5 by either JAK kinase inhibitor application or direct STAT5 inhibitor lead structure development and combinatorial drug action. Inhibitor work translates findings from basic research towards clinical application. We follow different strategies to inhibit hyperactive STAT5 activation in patient derived cells or transgenic mouse models that serve for test systems in pre-clinical evaluation.

欢迎广大师生前来参加！

                                                                                                                                       中国医学科学院医学实验动物研究所

                                                                                                                                                 2017年2月17日